Monsanto Co. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co.

MTC 2.800

+13.8%

Nov 28 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John F Beule who wrote (740)	12/9/1998 4:24:00 PM
From: Anthony Wong	Read Replies (1) of 2539

NDA for Vioxx submitted to FDA on Nov. 23..around 6 months behind Celebrex, even if Vioxx is given priority review. Excerpt from Merck's new release: The company also revealed new data on VIOXX™ (rofecoxib) -- its once- daily, anti-inflammatory COX-2-specific inhibitor for the treatment of the signs and symptoms of osteoarthritis and the relief of pain -- and confirmed it had submitted a New Drug Application to the U.S. Food and Drug Administration on November 23. Merck expects to have filed similar regulatory applications worldwide by the end of the year. News Release - New Products to Drive Revenue and Earnings Growth, Merck Tells Analysts; New Data Released on Investigational Medicine for Osteoarthritis and Pain biz.yahoo.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next